echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Pediatr Blood Cancer: Radiotherapy combined with VPA and bevacizumab in the treatment of glioma is well tolerated

    Pediatr Blood Cancer: Radiotherapy combined with VPA and bevacizumab in the treatment of glioma is well tolerated

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The prognosis of high-grade glioma (HGG) and diffuse intrinsic glioma (DIPG) is still not optimistic.


    Child Vascular Diagnosis

    From September 2009 to August 2015, 38 children with DIPG and HGG (20 in the DIPG group and 18 in the HGG group) aged 3-21 years were enrolled in the study to receive radiotherapy and VPA at a dose of 15 mg/kg/day.


     

    The results showed that during radiotherapy and VPA, adverse reactions of grade ≥3 that required stopping or modifying the VPA dose included grade 3 thrombocytopenia (1), grade 3 weight gain (1), and grade 3 pancreatitis (1).


    thrombus

     

    The median event-free survival (EFS) and overall survival (OS) in the DIPG group were 7.


    In summary, the results of this study show that radiotherapy combined with VPA and bevacizumab is well tolerated, but it does not seem to improve EFS or OS in children with DIPG or HGG.


     

    Original source:

     

    Jack Meng-Fen Su, et al.


    ncbi.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.